Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265


Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas.

Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA, Kang J, Assanah M, McKhann GM, Sisti MB, McCormick PC, Canoll P, Bruce JN.

Neurosurgery. 2008 Feb;62(2):505-14; discussion 514-5. doi: 10.1227/01.neu.0000316019.28421.95.


Limits of CD133 as a marker of glioma self-renewing cells.

Clément V, Dutoit V, Marino D, Dietrich PY, Radovanovic I.

Int J Cancer. 2009 Jul 1;125(1):244-8. doi: 10.1002/ijc.24352.


Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma.

Rebetz J, Tian D, Persson A, Widegren B, Salford LG, Englund E, Gisselsson D, Fan X.

PLoS One. 2008 Apr 9;3(4):e1936. doi: 10.1371/journal.pone.0001936.


CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas.

Bexell D, Gunnarsson S, Siesjö P, Bengzon J, Darabi A.

Int J Cancer. 2009 Jul 1;125(1):15-22. doi: 10.1002/ijc.24306.


A2B5 cells from human glioblastoma have cancer stem cell properties.

Tchoghandjian A, Baeza N, Colin C, Cayre M, Metellus P, Beclin C, Ouafik L, Figarella-Branger D.

Brain Pathol. 2010 Jan;20(1):211-21. doi: 10.1111/j.1750-3639.2009.00269.x.


CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors.

Beier D, Wischhusen J, Dietmaier W, Hau P, Proescholdt M, Brawanski A, Bogdahn U, Beier CP.

Brain Pathol. 2008 Jul;18(3):370-7. doi: 10.1111/j.1750-3639.2008.00130.x.


Targeting cancer stem cells through L1CAM suppresses glioma growth.

Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB, Rich JN.

Cancer Res. 2008 Aug 1;68(15):6043-8. doi: 10.1158/0008-5472.CAN-08-1079.


ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.

Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE.

PLoS One. 2011;6(6):e20636. doi: 10.1371/journal.pone.0020636.


A distinct subpopulation within CD133 positive brain tumor cells shares characteristics with endothelial progenitor cells.

Choi SA, Wang KC, Phi JH, Lee JY, Park CK, Park SH, Kim SK.

Cancer Lett. 2012 Nov 28;324(2):221-30. doi: 10.1016/j.canlet.2012.05.026.


What is the clinical value of cancer stem cell markers in gliomas?

Dahlrot RH, Hermansen SK, Hansen S, Kristensen BW.

Int J Clin Exp Pathol. 2013;6(3):334-48. Review.


CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays.

He J, Liu Y, Zhu T, Zhu J, Dimeco F, Vescovi AL, Heth JA, Muraszko KM, Fan X, Lubman DM.

Mol Cell Proteomics. 2012 Jun;11(6):M111.010744. doi: 10.1074/mcp.M111.010744.


CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.

Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R.

Stem Cells. 2009 Dec;27(12):2875-83. doi: 10.1002/stem.236.


Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.

Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A, Nuti M, Pierelli L, Testa U, Scambia G, Ferrandina G.

Clin Cancer Res. 2009 Jul 1;15(13):4299-311. doi: 10.1158/1078-0432.CCR-08-1883.


Study on the proliferation and drug-resistance of human brain tumor stem-like cells.

Qin K, Jiang X, Zou Y, Wang J, Qin L, Zeng Y.

Cell Mol Neurobiol. 2010 Aug;30(6):955-60. doi: 10.1007/s10571-010-9525-9.


CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Wang J, Sakariassen PØ, Tsinkalovsky O, Immervoll H, Bøe SO, Svendsen A, Prestegarden L, Røsland G, Thorsen F, Stuhr L, Molven A, Bjerkvig R, Enger PØ.

Int J Cancer. 2008 Feb 15;122(4):761-8.


How powerful is CD133 as a cancer stem cell marker in brain tumors?

Cheng JX, Liu BL, Zhang X.

Cancer Treat Rev. 2009 Aug;35(5):403-8. doi: 10.1016/j.ctrv.2009.03.002. Review.


Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.

Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, Fang J.

J Exp Clin Cancer Res. 2008 Dec 24;27:85. doi: 10.1186/1756-9966-27-85.


The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma.

Hua W, Yao Y, Chu Y, Zhong P, Sheng X, Xiao B, Wu J, Yang B, Mao Y, Zhou L.

J Neurooncol. 2011 Nov;105(2):149-57. doi: 10.1007/s11060-011-0572-y.

Items per page

Supplemental Content

Support Center